The receptor binding domain of MERS-CoV: the dawn of vaccine and treatment development

Nan Zhou; Yun Zhang; Jin Chun Zhang; Ling Feng; Jin Ku Bao

doi:10.1016/j.jfma.2013.11.006

The receptor binding domain of MERS-CoV: the dawn of vaccine and treatment development

Nan Zhou, Yun Zhang, Jin Chun Zhang, Ling Feng, Jin Ku Bao^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

20 Citations (Scopus)

Abstract

The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another "SARS-like" threat to the world. It has an extremely high death rate (~50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.

Original language	English
Pages (from-to)	143-147
Number of pages	5
Journal	Journal of the Formosan Medical Association
Volume	113
Issue number	3
DOIs	https://doi.org/10.1016/j.jfma.2013.11.006
Publication status	Published - Mar 2014
Externally published	Yes

Keywords

coronavirus
drug design
Middle East
vaccines

Access to Document

10.1016/j.jfma.2013.11.006

Cite this

@article{d6bd2aa52abd42d29fb95da9f5cf77a5,

title = "The receptor binding domain of MERS-CoV: the dawn of vaccine and treatment development",

abstract = "The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another {"}SARS-like{"} threat to the world. It has an extremely high death rate (~50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.",

keywords = "coronavirus, drug design, Middle East, vaccines",

author = "Nan Zhou and Yun Zhang and Zhang, {Jin Chun} and Ling Feng and Bao, {Jin Ku}",

year = "2014",

month = mar,

doi = "10.1016/j.jfma.2013.11.006",

language = "English",

volume = "113",

pages = "143--147",

journal = "Journal of the Formosan Medical Association",

issn = "0929-6646",

publisher = "Excerpta Medica Asia Ltd.",

number = "3",

}

TY - JOUR

T1 - The receptor binding domain of MERS-CoV

T2 - the dawn of vaccine and treatment development

AU - Zhou, Nan

AU - Zhang, Yun

AU - Zhang, Jin Chun

AU - Feng, Ling

AU - Bao, Jin Ku

PY - 2014/3

Y1 - 2014/3

N2 - The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another "SARS-like" threat to the world. It has an extremely high death rate (~50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.

AB - The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another "SARS-like" threat to the world. It has an extremely high death rate (~50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.

KW - coronavirus

KW - drug design

KW - Middle East

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=84895861186&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2013.11.006

DO - 10.1016/j.jfma.2013.11.006

M3 - Review article

C2 - 24342026

AN - SCOPUS:84895861186

SN - 0929-6646

VL - 113

SP - 143

EP - 147

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

IS - 3

ER -

The receptor binding domain of MERS-CoV: the dawn of vaccine and treatment development

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this